(Nasdaq: MIRM), a leading rare disease company, today announced completion of enrollment in the Phase 3 AZURE-1 study and ...

LFT slightly high. There is no pain. No yellowing of the eyes. No weakness. So it is easy to brush it aside. But the liver ...